Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)-Reference-Cited by-同舟云学术

Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)

Published:2017-08-01 Issue:8 Volume:12 Page:e0180651
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Messina Silvia,Solaro Claudio,Righini Isabella,Bergamaschi Roberto,Bonavita Simona,Bossio Roberto Bruno,Brescia Morra Vincenzo,Costantino Gianfranco,Cavalla Paola,Centonze Diego,Comi Giancarlo,Cottone Salvatore,Danni Maura Chiara,Francia Ada,Gajofatto Alberto,Gasperini Claudio,Zaffaroni Mauro,Petrucci Loredana,Signoriello Elisabetta,Maniscalco Giorgia Teresa,Spinicci Gabriella,Matta Manuela,Mirabella Massimiliano,Pedà Graziella,Castelli Letizia,Rovaris Marco,Sessa Edoardo,Spitaleri Daniele,Paolicelli Damiano,Granata Alfredo,Zappia Mario,Patti Francesco^ORCID,

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference20 articles.

1. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study;R Arroyo;Expert Rev Pharmacoecon Outcomes Res,2011

2. Symptoms, prevalence and impact of multiple sclerosis in younger patients: a multinational survey;F Patti;Neuroepidemiology,2014

3. Overview of MS spasticity;C Pozzilli;European neurology,2014

4. Treatments for spasticity and pain in multiple sclerosis: a systematic review;S Beard;Health technology assessment,2003

5. Anti-spasticity agents for multiple sclerosis;DT Shakespeare;The Cochrane database of systematic reviews,2003

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real‐world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described ‘spasticity‐plus syndrome’;European Journal of Neurology;2022-06-07

2. Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap;Neurodegenerative Disease Management;2022-06

3. Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination;Biomedicines;2022-02-24

4. Review of available data for the efficacy and effectiveness of nabiximols oromucosal spray (Sativex) in multiple sclerosis patients with moderate to severe spasticity;Neurodegenerative Diseases;2021-11-03

5. Δ 9 ‐Tetrahydrocannabinol promotes functional remyelination in the mouse brain;British Journal of Pharmacology;2021-08-02